Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer death. Although the treatment modalities are improving, the prognosis of PDAC continues to be poor. Therefore, early detection of PDAC or its precursor lesions may be the best way to improve patient survival. PDACs have several different precursor lesions, including pancreatic intraepithelial neoplasias (PanINs), intraductal papillary mucinous neoplasms (IPMNs), intraductal tubulopapillary neoplasms (ITPNs), intraductal oncocytic papillary neoplasms (IOPNs), and mucinous cystic neoplasms (MCNs). PanINs cannot be identified using imaging modalities, while the other lesions are radiologically detectable. These precursor lesions are categorized based on structural and cytological atypia as low-grade and high-grade lesions. We discuss recent updates regarding histopathological and molecular pathological overviews of PDAC precursor lesions. Better understanding of such lesions may contribute to earlier detection of PDAC or its precursor lesions and improve PDAC patient survival.

1.
Rahib L, Smith BD, Aizenberg R, et al.: Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014;74:2913-2921.
[PubMed]
2.
Siegel RL, Miller KD ,Jemal A: Cancer statistics, 2018. CA Cancer J Clin 2018;68:7-30.
[PubMed]
3.
Canto MI, Almario JA, Schulick RD, et al.: Risk of neoplastic progression in individuals at high risk for pancreatic cancer undergoing long-term surveillance. Gastroenterology 2018;155:740-751.
[PubMed]
4.
Canto MI, Goggins M, Hruban RH, et al.: Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 2006;4:766-81; quiz 665.
[PubMed]
5.
Basturk O, Hong SM, Wood LD, et al.: A revised classification system and recommendations from the Baltimore Consensus Meeting for neoplastic precursor lesions in the pancreas. Am J Surg Pathol 2015;39:1730-1741.
[PubMed]
6.
Hruban RH, Adsay NV, Albores-Saavedra J, et al.: Pancreatic intraepithelial neoplasia: A new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 2001;25:579-586.
[PubMed]
7.
Hruban RH, Takaori K, Klimstra DS, et al.: An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 2004;28:977-987.
[PubMed]
8.
Andea A, Sarkar F ,Adsay VN: Clinicopathological correlates of pancreatic intraepithelial neoplasia: A comparative analysis of 82 cases with and 152 cases without pancreatic ductal adenocarcinoma. Mod Pathol 2003;16:996-1006.
[PubMed]
9.
Hruban RH, Takaori K, Canto M, et al.: Clinical importance of precursor lesions in the pancreas. J Hepatobiliary Pancreat Surg 2007;14:255-263.
[PubMed]
10.
Pittman ME, Rao R ,Hruban RH: Classification, morphology, molecular pathogenesis, and outcome of premalignant lesions of the pancreas. Arch Pathol Lab Med 2017;141:1606-1614.
[PubMed]
11.
Matthaei H, Hong SM, Mayo SC, et al.: Presence of pancreatic intraepithelial neoplasia in the pancreatic transection margin does not influence outcome in patients with R0 resected pancreatic cancer. Ann Surg Oncol 2011;18:3493-3499.
[PubMed]
12.
Brat DJ, Lillemoe KD, Yeo CJ, et al.: Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. Am J Surg Pathol 1998;22:163-169.
[PubMed]
13.
Adsay NV, Merati K, Andea A, et al.: The dichotomy in the preinvasive neoplasia to invasive carcinoma sequence in the pancreas: differential expression of MUC1 and MUC2 supports the existence of two separate pathways of carcinogenesis. Mod Pathol 2002;15:1087-1095.
[PubMed]
14.
Maitra A, Adsay NV, Argani P, et al.: Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol 2003;16:902-912.
[PubMed]
15.
Basturk O, Chung SM, Hruban RH, et al.: Distinct pathways of pathogenesis of intraductal oncocytic papillary neoplasms and intraductal papillary mucinous neoplasms of the pancreas. Virchows Arch 2016;469:523-532.
[PubMed]
16.
Hruban RH, Goggins M, Parsons J, et al.: Progression model for pancreatic cancer. Clin Cancer Res 2000;6:2969-2972.
[PubMed]
17.
Murphy SJ, Hart SN, Lima JF, et al.: Genetic alterations associated with progression from pancreatic intraepithelial neoplasia to invasive pancreatic tumor. Gastroenterology 2013;145:1098-1109 e1.
[PubMed]
18.
Hong SM, Heaphy CM, Shi C, et al.: Telomeres are shortened in acinar-to-ductal metaplasia lesions associated with pancreatic intraepithelial neoplasia but not in isolated acinar-to-ductal metaplasias. Mod Pathol 2011;24:256-266.
[PubMed]
19.
Kanda M, Matthaei H, Wu J, et al.: Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology 2012;142:730-733 e9.
[PubMed]
20.
Feldmann G, Beaty R, Hruban RH, et al.: Molecular genetics of pancreatic intraepithelial neoplasia. J Hepatobiliary Pancreat Surg 2007;14:224-232.
[PubMed]
21.
Caldas C, Hahn SA, da Costa LT, et al.: Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994;8:27-32.
[PubMed]
22.
Wilentz RE, Iacobuzio-Donahue CA, Argani P, et al.: Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: Evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 2000;60:2002-2006.
[PubMed]
23.
Luttges J, Galehdari H, Brocker V, et al.: Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis. Am J Pathol 2001;158:1677-1683.
[PubMed]
24.
Hosoda W, Chianchiano P, Griffin JF, et al.: Genetic analyses of isolated high-grade pancreatic intraepithelial neoplasia (HG-PanIN) reveal paucity of alterations in TP53 and SMAD4. J Pathol 2017;242:16-23.
[PubMed]
25.
Yokode M, Akita M, Fujikura K, et al.: High-grade PanIN presenting with localised stricture of the main pancreatic duct: A clinicopathological and molecular study of 10 cases suggests a clue for the early detection of pancreatic cancer. Histopathology 2018;73:247-258.
[PubMed]
26.
Matthaei H, Wu J, Dal Molin M, et al.: GNAS sequencing identifies IPMN-specific mutations in a subgroup of diminutive pancreatic cysts referred to as ‘incipient IPMNs'. Am J Surg Pathol 2014;38:360-363.
[PubMed]
27.
Tanase H, Suda K, Yamasaki S, et al.: Intraductal low papillary histological pattern of carcinoma component shows intraductal spread in invasive carcinoma of the pancreas. J Hepatobiliary Pancreat Surg 2006;13:235-238.
[PubMed]
28.
Hong SM, Goggins M, Wolfgang CL, et al.: Vascular invasion in infiltrating ductal adenocarcinoma of the pancreas can mimic pancreatic intraepithelial neoplasia: A histopathologic study of 209 cases. Am J Surg Pathol 2012;36:235-241.
[PubMed]
29.
D'Angelica M, Brennan MF, Suriawinata AA, et al.: Intraductal papillary mucinous neoplasms of the pancreas: An analysis of clinicopathologic features and outcome. Ann Surg 2004;239:400-408.
[PubMed]
30.
Rezaee N, Barbon C, Zaki A, et al.: Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma. HPB (Oxford) 2016;18:236-246.
[PubMed]
31.
Loftus EV Jr, Olivares-Pakzad BA, Batts KP, et al.: Intraductal papillary-mucinous tumors of the pancreas: Clinicopathologic features, outcome, and nomenclature. Members of the Pancreas Clinic, and Pancreatic Surgeons of Mayo Clinic. Gastroenterology 1996;110:1909-1918.
[PubMed]
32.
Pelaez-Luna M, Chari ST, Smyrk TC, et al.: Do consensus indications for resection in branch duct intraductal papillary mucinous neoplasm predict malignancy? A study of 147 patients. Am J Gastroenterol 2007;102:1759-1764.
[PubMed]
33.
Sohn TA, Yeo CJ, Cameron JL, et al.: Intraductal papillary mucinous neoplasms of the pancreas: An increasingly recognized clinicopathologic entity. Ann Surg 2001;234:313-321; discussion 321-322.
[PubMed]
34.
Adsay V, Mino-Kenudson M, Furukawa T, et al.: Pathologic evaluation and reporting of intraductal papillary mucinous neoplasms of the pancreas and other tumoral intraepithelial neoplasms of pancreatobiliary tract: Recommendations of Verona Consensus Meeting. Ann Surg 2016;263:162-177.
[PubMed]
35.
Schaberg KB, DiMaio MA ,Longacre TA: Intraductal papillary mucinous neoplasms often contain epithelium from multiple subtypes and/or are unclassifiable. Am J Surg Pathol 2016;40:44-50.
[PubMed]
36.
Bosman FT, Carneiro F, Hruban RH, et al., WHO classification of tumours of the digestive system, 4th ed. Intrenation Agency for Research on Cancer, Lyon, 2010.
37.
Tanaka M, Fernandez-del Castillo C, Adsay V, et al.: International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 2012;12:183-197.
[PubMed]
38.
Tanaka M, Fernandez-Del Castillo C, Kamisawa T, et al.: Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology 2017;17:738-753.
[PubMed]
39.
Ban S, Naitoh Y, Mino-Kenudson M, et al.: Intraductal papillary mucinous neoplasm (IPMN) of the pancreas: Its histopathologic difference between 2 major types. Am J Surg Pathol 2006;30:1561-1569.
[PubMed]
40.
Furukawa T, Kloppel G, Volkan Adsay N, et al.: Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch 2005;447:794-799.
[PubMed]
41.
Nakamura A, Horinouchi M, Goto M, et al.: New classification of pancreatic intraductal papillary-mucinous tumour by mucin expression: Its relationship with potential for malignancy. J Pathol 2002;197:201-210.
[PubMed]
42.
Basturk O, Khayyata S, Klimstra DS, et al.: Preferential expression of MUC6 in oncocytic and pancreatobiliary types of intraductal papillary neoplasms highlights a pyloropancreatic pathway, distinct from the intestinal pathway, in pancreatic carcinogenesis. Am J Surg Pathol 2010;34:364-370.
[PubMed]
43.
Shi C ,Hruban RH: Intraductal papillary mucinous neoplasm. Hum Pathol 2012;43:1-16.
[PubMed]
44.
Kloppel G, Basturk O, Schlitter AM, et al.: Intraductal neoplasms of the pancreas. Semin Diagn Pathol 2014;31:452-466.
[PubMed]
45.
Furukawa T, Hatori T, Fujita I, et al.: Prognostic relevance of morphological types of intraductal papillary mucinous neoplasms of the pancreas. Gut 2011;60:509-516.
[PubMed]
46.
Distler M, Kersting S, Niedergethmann M, et al.: Pathohistological subtype predicts survival in patients with intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Ann Surg 2013;258:324-330.
[PubMed]
47.
Adsay NV, Merati K, Basturk O, et al.: Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: Delineation of an ‘intestinal' pathway of carcinogenesis in the pancreas. Am J Surg Pathol 2004;28:839-848.
[PubMed]
48.
Bellizzi AM ,Stelow EB: Pancreatic cytopathology: A practical approach and review. Arch Pathol Lab Med 2009;133:388-404.
[PubMed]
49.
Genevay M, Mino-Kenudson M, Yaeger K, et al.: Cytology adds value to imaging studies for risk assessment of malignancy in pancreatic mucinous cysts. Ann Surg 2011;254:977-983.
[PubMed]
50.
Stelow EB, Shami VM, Abbott TE, et al.: The use of fine needle aspiration cytology for the distinction of pancreatic mucinous neoplasia. Am J Clin Pathol 2008;129:67-74.
[PubMed]
51.
Schonleben F, Qiu W, Bruckman KC, et al.: BRAF and KRAS gene mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC) of the pancreas. Cancer Lett 2007;249:242-248.
[PubMed]
52.
Uemura K, Hiyama E, Murakami Y, et al.: Comparative analysis of K-ras point mutation, telomerase activity, and p53 overexpression in pancreatic tumours. Oncol Rep 2003;10:277-283.
[PubMed]
53.
Springer S, Wang Y, Dal Molin M, et al.: A combination of molecular markers and clinical features improve the classification of pancreatic cysts. Gastroenterology 2015;149:1501-1510.
[PubMed]
54.
Reid MD, Saka B, Balci S, et al.: Molecular genetics of pancreatic neoplasms and their morphologic correlates: An update on recent advances and potential diagnostic applications. Am J Clin Pathol 2014;141:168-180.
[PubMed]
55.
Furukawa T, Kuboki Y, Tanji E, et al.: Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci Rep 2011;1:161.
[PubMed]
56.
Amato E, Molin MD, Mafficini A, et al.: Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. J Pathol 2014;233:217-227.
[PubMed]
57.
Sakamoto H, Kuboki Y, Hatori T, et al.: Clinicopathological significance of somatic RNF43 mutation and aberrant expression of ring finger protein 43 in intraductal papillary mucinous neoplasms of the pancreas. Mod Pathol 2015;28:261-267.
[PubMed]
58.
Abe T, Fukushima N, Brune K, et al.: Genome-wide allelotypes of familial pancreatic adenocarcinomas and familial and sporadic intraductal papillary mucinous neoplasms. Clin Cancer Res 2007;13:6019-6025.
[PubMed]
59.
Mueller J, Gansauge S ,Mattfeldt T: P53 mutation but not p16/MTS1 mutation occurs in intraductal papillary mucinous tumors of the pancreas. Hepatogastroenterology 2003;50:541-544.
[PubMed]
60.
Attiyeh MA, Fernandez-Del Castillo C, Al Efishat M, et al.: Development and validation of a multi-institutional preoperative nomogram for predicting grade of dysplasia in intraductal papillary mucinous neoplasms (IPMNs) of the pancreas: A report from the Pancreatic Surgery Consortium. Ann Surg 2018;267:157-163.
[PubMed]
61.
Grutzmann R, Niedergethmann M, Pilarsky C, et al.: Intraductal papillary mucinous tumors of the pancreas: Biology, diagnosis, and treatment. Oncologist 2010;15:1294-1309.
[PubMed]
62.
Koh YX, Chok AY, Zheng HL, et al.: Systematic review and meta-analysis comparing the surgical outcomes of invasive intraductal papillary mucinous neoplasms and conventional pancreatic ductal adenocarcinoma. Ann Surg Oncol 2014;21:2782-2800.
[PubMed]
63.
Nara S, Shimada K, Kosuge T, et al.: Minimally invasive intraductal papillary-mucinous carcinoma of the pancreas: Clinicopathologic study of 104 intraductal papillary-mucinous neoplasms. Am J Surg Pathol 2008;32:243-255.
[PubMed]
64.
Schnelldorfer T, Sarr MG, Nagorney DM, et al.: Experience with 208 resections for intraductal papillary mucinous neoplasm of the pancreas. Arch Surg 2008;143:639-646; discussion 646.
[PubMed]
65.
Rooney SL ,Shi J: Intraductal tubulopapillary neoplasm of the pancreas: An update from a pathologist's perspective. Arch Pathol Lab Med 2016;140:1068-1073.
[PubMed]
66.
Basturk O, Adsay V, Askan G, et al.: Intraductal Tubulopapillary neoplasm of the pancreas: A clinicopathologic and immunohistochemical analysis of 33 cases. Am J Surg Pathol 2017;41:313-325.
[PubMed]
67.
Yamaguchi H, Kuboki Y, Hatori T, et al.: Somatic mutations in PIK3CA and activation of AKT in intraductal tubulopapillary neoplasms of the pancreas. Am J Surg Pathol 2011;35:1812-1817.
[PubMed]
68.
Yamaguchi H, Shimizu M, Ban S, et al.: Intraductal tubulopapillary neoplasms of the pancreas distinct from pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 2009;33:1164-1172.
[PubMed]
69.
Kim H ,Ro JY: Intraductal tubulopapillary neoplasm of the pancreas: An overview. Arch Pathol Lab Med 2018;142:420-423.
[PubMed]
70.
Bosman FT CF, Hruban RH, Theise ND (eds), WHO classification of tumours of the digestive system, 4th ed. International Agency for Research on Cancer, Lyon, 2010.
[PubMed]
71.
Kolby D, Thilen J, Andersson R, et al.: Multifocal intraductal tubulopapillary neoplasm of the pancreas with total pancreatectomy: Report of a case and review of literature. Int J Clin Exp Pathol 2015;8:9672-9680.
[PubMed]
72.
Yamaguchi H, Kuboki Y, Hatori T, et al.: The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant. J Pathol 2013;231:335-341.
[PubMed]
73.
Adsay NV, Adair CF, Heffess CS, et al.: Intraductal oncocytic papillary neoplasms of the pancreas. Am J Surg Pathol 1996;20:980-994.
[PubMed]
74.
Marchegiani G, Mino-Kenudson M, Ferrone CR, et al.: Oncocytic-type intraductal papillary mucinous neoplasms: A unique malignant pancreatic tumor with good long-term prognosis. J Am Coll Surg 2015;220:839-844.
[PubMed]
75.
Adsay VN: Cystic lesions of the pancreas. Mod Pathol 2007;20(Suppl 1):S71-93.
[PubMed]
76.
Basturk O, Tan M, Bhanot U, et al.: The oncocytic subtype is genetically distinct from other pancreatic intraductal papillary mucinous neoplasm subtypes. Mod Pathol 2016;29:1058-1069.
[PubMed]
77.
Mohri D, Asaoka Y, Ijichi H, et al.: Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression. J Gastroenterol 2012;47:203-213.
[PubMed]
78.
Xiao HD, Yamaguchi H, Dias-Santagata D, et al.: Molecular characteristics and biological behaviours of the oncocytic and pancreatobiliary subtypes of intraductal papillary mucinous neoplasms. J Pathol 2011;224:508-516.
[PubMed]
79.
Wu J, Jiao Y, Dal Molin M, et al.: Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci USA 2011;108:21188-21193.
[PubMed]
80.
Thompson LD, Becker RC, Przygodzki RM, et al.: Mucinous cystic neoplasm (mucinous cystadenocarcinoma of low-grade malignant potential) of the pancreas: A clinicopathologic study of 130 cases. Am J Surg Pathol 1999;23:1-16.
[PubMed]
81.
Zhelnin K, Xue Y, Quigley B, et al.: Nonmucinous biliary epithelium is a frequent finding and is often the predominant epithelial type in mucinous cystic neoplasms of the pancreas and liver. Am J Surg Pathol 2017;41:116-120.
[PubMed]
82.
Jang KT, Park SM, Basturk O, et al.: Clinicopathologic characteristics of 29 invasive carcinomas arising in 178 pancreatic mucinous cystic neoplasms with ovarian-type stroma: Implications for management and prognosis. Am J Surg Pathol 2015;39:179-187.
[PubMed]
83.
Sarr MG, Carpenter HA, Prabhakar LP, et al.: Clinical and pathologic correlation of 84 mucinous cystic neoplasms of the pancreas: Can one reliably differentiate benign from malignant (or premalignant) neoplasms? Ann Surg 2000;231:205-212.
[PubMed]
84.
Yamao K, Yanagisawa A, Takahashi K, et al.: Clinicopathological features and prognosis of mucinous cystic neoplasm with ovarian-type stroma: a multi-institutional study of the Japan pancreas society. Pancreas 2011;40:67-71.
[PubMed]
85.
van den Berg W, Tascilar M, Offerhaus GJ, et al.: Pancreatic mucinous cystic neoplasms with sarcomatous stroma: Molecular evidence for monoclonal origin with subsequent divergence of the epithelial and sarcomatous components. Mod Pathol 2000;13:86-91.
[PubMed]
86.
Adsay NV, Pierson C, Sarkar F, et al.: Colloid (mucinous noncystic) carcinoma of the pancreas. Am J Surg Pathol 2001;25:26-42.
[PubMed]
87.
Zamboni G, Scarpa A, Bogina G, et al.: Mucinous cystic tumors of the pancreas: Clinicopathological features, prognosis, and relationship to other mucinous cystic tumors. Am J Surg Pathol 1999;23:410-422.
[PubMed]
88.
Lam MM, Swanson PE, Upton MP, et al.: Ovarian-type stroma in hepatobiliary cystadenomas and pancreatic mucinous cystic neoplasms: An immunohistochemical study. Am J Clin Pathol 2008;129:211-218.
[PubMed]
89.
Brugge WR: Diagnosis and management of cystic lesions of the pancreas. J Gastrointest Oncol 2015;6:375-388.
[PubMed]
90.
Di Paola V, Manfredi R, Mehrabi S, et al.: Pancreatic mucinous cystoadenomas and cystoadenocarcinomas: differential diagnosis by means of MRI. Br J Radiol 2016;89:20150536.
[PubMed]
91.
Crippa S, Fernandez-Del Castillo C, Salvia R, et al.: Mucin-producing neoplasms of the pancreas: An analysis of distinguishing clinical and epidemiologic characteristics. Clin Gastroenterol Hepatol 2010;8:213-219.
[PubMed]
You do not currently have access to this content.